Landmark Science announces research to be presented at ISPE 2025
At this year's conference, Landmark Science spotlights real-world evidence's power to drive GLP-1 and Wegovy insights in Medicare and shape...
At this year's conference, Landmark Science spotlights real-world evidence's power to drive GLP-1 and Wegovy insights in Medicare and shape...
National in-home care franchise expands access to dementia care services through new CMS-backed program OMAHA, Neb., Aug. 18, 2025 /PRNewswire/...
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor...
Two of the region’s leading organizations team up to elevate community-based care options for seniors across Tampa Bay.TAMPA, Fla., Aug....
SPARKS, Md., Aug. 15, 2025 /PRNewswire/ -- Fundamental Administrative Services, LLC ("Fundamental") issued notice of a data security event that...
Our software solution will provide states with modern, flexible technology to implement Medicaid work requirements while achieving human-centered outcomes and...
New partnership powers faster, more compliant, and member-centered care for Care Management, Utilization Management, and more PLANO, Texas, Aug. 14,...
LOUISVILLE, Ky., Aug. 14, 2025 /PRNewswire/ -- RAAPID, a leading provider of AI-powered risk adjustment solutions, today announced its participation...
Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk...
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of...
AI innovation in population health continues to fuel Lightbeam's momentum, earning recognition among the fastest-growing private companies in America DALLAS,...
Program Designed to Increase Use of Recommended Medication Therapy by Connecting with Providers in Workflow LOUISVILLE, Ky. and ARLINGTON, Va.,...
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)...
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)...
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted...
Founded by a team of physicians and AI experts, EasyPA launched the nation's first fully operational prior authorization (PA) platform...
Technology-enabled solution expands access to high-touch, personalized dementia care at home BOSTON, Aug. 12, 2025 /PRNewswire/ -- Neuroglee Health, a...
NEW YORK, NY / ACCESS Newswire / August 12, 2025 / Inc., the leading media brand and playbook for the...
BOSTON--(BUSINESS WIRE)--#histologymatters--Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive...
Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on...